Navigation Links
JAZZ PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2013 FINANCIAL RESULTS
Date:5/7/2013

DUBLIN, May 7, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter ended March 31, 2013, updated 2013 financial guidance and key additions to its board of directors.

"During the first quarter, we continued to deliver strong top and bottom line growth fueled by growing sales of Xyrem and Erwinaze," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals plc.  "We have made substantial progress in the execution of our strategy to maximize the potential of our product portfolio while further strengthening our cash position, positioning us to pursue promising corporate development opportunities and share repurchases."

Adjusted net income for the first quarter of 2013 was $84.4 million, or $1.37 per diluted share, compared to $51.7 million, or $0.89 per diluted share, for the first quarter of 2012. 

Both GAAP income from continuing operations and GAAP net income for the first quarter of 2013 were $43.4 million, or $0.71 per diluted share.  GAAP income from continuing operations for the first quarter of 2012 was $30.2 million, or $0.52 per diluted share, and GAAP net income for the first quarter of 2012 was $27.7 million, or $0.48 per diluted share. 

GAAP net income for the first quarter of 2013 included various acquisition-related expenses, including the change in fair value of contingent consideration, upfront license fees, transaction, integration and restructuring expenses, as well as certain non-cash expenses and income tax adjustments.  GAAP net income for the first quarter of 2012 included various acquisition-related expenses, including transaction and integration expenses, as well as certain non-cash expenses and discontinued operations.  Reconciliations of applicable GAAP to non-GAAP adjusted information are included with
'/>"/>

SOURCE Jazz Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Isis Pharmaceuticals Announces Proposed Public Offering of Common Stock
2. Alexza Pharmaceuticals to Present at Antiepileptic Drug and Device Trials (AED) XII Conference Highlighting Advances in the Treatment of Epilepsy
3. Kinex Pharmaceuticals and Zenith Technology Corporation announce the execution of a collaborative licensing agreement
4. Isis Pharmaceuticals Announces the Initiation of a Clinical Study of ISIS-STAT3 Rx in Patients with Liver Cancer
5. AcelRx Pharmaceuticals to Hold First Quarter 2013 Financial Results Conference Call and Webcast on May 8, 2013
6. Valeant Pharmaceuticals Provides Efinconazole Update
7. Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2013 Financial Results
8. Cumberland Pharmaceuticals Reports First Quarter Financial Results
9. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
10. Webcast Alert: Isis Pharmaceuticals First Quarter 2013 Financial Results Conference Call
11. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... -- According to a new market research ... Type (Protein & Genetic Biomarkers) Profiling Technology (Proteomics, Genomics, ... - Global Forecast to 2020", published by MarketsandMarkets, The ... Million USD by 2020 at a CAGR of 13.9% ... Browse 191 Tables and 38 F ...
(Date:8/28/2015)... -- Today, in final recognition of the Centers for Disease ... Contacts is sharing how to keep lens cases clean.  ... do not properly care for their lens cases are ... Most contact lens wearers understand the importance of ... is sometimes overlooked.  When proper steps to clean a ...
(Date:8/28/2015)... Research and Markets ( http://www.researchandmarkets.com/research/sqh7xc/investigation ) ... on China,s Ranibizumab Market, 2012-2019" report to their ... by CFDA to treat wet age- related macular degeneration ... Novartis, is available in the Chinese market. However, in ... the treatment of wet AMD in China ...
Breaking Medicine Technology:Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 2Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 3Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 4Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 51-800 Contacts Shares Tips on How to Clean Lens Cases 2Investigation Report on China's Ranibizumab Market, 2012-2019 2
... - IgG1 monoclonal,antibodies developed by ImClone Systems ... total presentations at the recently concluded,98th Annual ... Research,(AACR), including seven oral presentations and 37 ... the focus of,two back-to-back oral presentations leading ...
... ANGELES--(BUSINESS WIRE)--Apr 19, 2007 - Abraxis ... discussed results from two pre-clinical studies ... and,rationale for combining nab-paclitaxel (ABRAXANE(R) for ... (albumin-bound)) with VEGF inhibitor drugs like,bevacizumab ...
Cached Medicine Technology:ImClone Systems Showcases Extensive Research and Development,Program at the AACR Annual Meeting 2ImClone Systems Showcases Extensive Research and Development,Program at the AACR Annual Meeting 3ImClone Systems Showcases Extensive Research and Development,Program at the AACR Annual Meeting 4ImClone Systems Showcases Extensive Research and Development,Program at the AACR Annual Meeting 5Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 2Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 3Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 4Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 5
(Date:8/30/2015)... (PRWEB) , ... August 30, 2015 , ... Certified Nutrition ... Nutritional Products International and InHealth media is a global sales and communications firm ... are extremely pleased to continue our business relationship with Mr. Reid Eckert, as his ...
(Date:8/30/2015)... ... August 30, 2015 , ... ... devices for the treatment of prostate cancer, has announced the roll-out of its ... the treatment center in Puerto Vallarta, Mexico. , The Sonablate® technology currently in ...
(Date:8/29/2015)... ... August 30, 2015 , ... Electronic ... 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/electronicinformedconsent , The simple fact ... handwritten signature. , Clinical trial sites can now use audio, video ...
(Date:8/29/2015)... ... 2015 , ... It can be uncomfortable to wear boxers ... sweat. "In order to prevent these problems, I conceived of my design," said ... UNDERGARMENT provides optimal support for a male’s crotch. It improves comfort for the ...
(Date:8/29/2015)... ... August 29, 2015 , ... Brands like Toppik , Eau Thermale ... costs. , “Before, a threshold of $49.00 was required to qualify for free standard ... for free standard shipping for customers regardless of the item’s selling price.” , With ...
Breaking Medicine News(10 mins):Health News:Nutrition Guru Continues Relationship With Renowned Health and Wellness Company 2Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4Health News:Modified Men’s Underwear Promote More Comfort and Hygiene - Designed by InventHelp Client (LGI-1968) 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2
... Theranostics Health announced,that it has received ... of,Health (NIH) to commercialize microdissection including Laser ... cancer diagnostics,and companion diagnostics. Under the terms ... the customary license issue royalties, minimum annual,royalties, ...
... Infections That Would ... Period, Receives $6.0 Million From Gordon and Betty Moore Foundation ... Patient Safety and Quality Improvement Efforts, WALNUT ... 39 hospitals in five San,Francisco Bay Area counties, announced today that ...
... suicide is often perceived as the result of rejection ... by teenage suicide often look back for warning signs ... tragedy. With the recent teenage suicides in Bridgend, South ... strategies. However little attention is paid to those families ...
... A new nationwide clinician survey provides the first comprehensive ... usual for nonepileptic seizures (NES), laying the groundwork for ... neuropsychiatric disorder. , There is currently no standard ... seizure but is not caused by abnormal activity in ...
... Inc. (AIS), publisher of industry-leading newsletters Health Plan,Week, ... pleased to announce,publication of "Managed Medicare and Medicaid ... and almost 30 million Medicaid recipients,enrolled in managed ... other,companies with a stake in this market place ...
... celebration of Earth Day tomorrow, medical device company announces ... ... recycling programs., ENGLEWOOD, Colo., April 21 Baxa ... for,environmental harm and support sustainable resources. As a healthcare,products ...
Cached Medicine News:Health News:NIH Grants Exclusive License to Theranostics Health 2Health News:Competing San Francisco Bay Area Hospitals Demonstrate That Collaborative Efforts Contribute to Reduced Hospital Errors and Saved Lives 2Health News:Competing San Francisco Bay Area Hospitals Demonstrate That Collaborative Efforts Contribute to Reduced Hospital Errors and Saved Lives 3Health News:Competing San Francisco Bay Area Hospitals Demonstrate That Collaborative Efforts Contribute to Reduced Hospital Errors and Saved Lives 4Health News:Competing San Francisco Bay Area Hospitals Demonstrate That Collaborative Efforts Contribute to Reduced Hospital Errors and Saved Lives 5Health News:Teenage suicides: Study advocates greater family support 2Health News:Survey offers first-ever look at treatment practices for nonepileptic seizures 2Health News:New Medicare and Medicaid Data Released: Featuring Up-To-Date Enrollment Trends, State Initiatives, Regional Market Share and Prescription Drug Benefits 2Health News:Baxa Environmental Program Nets Significant Results 2Health News:Baxa Environmental Program Nets Significant Results 3